Raymond Cross, MD

IBD-Associated Arthritis is Associated With Concomitant Autoimmune and Inflammatory Disorders

1 Institute for Genome Sciences, University of Maryland School of Medicine, Silver Spring, Maryland, United States; 2 United States; 3 University of Maryland, Baltimore, Maryland, United ...

Madeline Alizadeh ;

Uni Wong ;

Bernadette C. Siaton ;

Seema A. Patil ;

Lauren V. George , PharmD, BCPS;

Jean-Pierre Raufman , MD;

William H. Scott ;

Erik C. von Rosenvinge ;

Jacques Ravel ;

Raymond Cross , MD;

01/11/2024

Podcast

IBD Drive Time: The Best of Digestive Disease Week Part 2

07/12/2023

Millie D. Long , MD, MPH;

Raymond Cross , MD;

Drs Raymond Cross and Millie Long continue their discussion about the best abstracts on inflammatory bowel disease presented at the Digestive Disease Week conference in May.

Drs Raymond Cross and Millie...

07/12/2023

Advances in Inflammatory Bowel Disease Network

Podcast

IBD Drive Time: The Best of Digestive Disease Week Part 1

07/11/2023

Raymond Cross , MD;

Millie D. Long , MD, MPH;

In the first of two episodes, Drs Millie Long and Raymond Cross discuss their choices of the best abstracts on inflammatory bowel disease from the Digestive Disease Week conference held in May.

In the first of two episodes,...

07/11/2023

Advances in Inflammatory Bowel Disease Network

Validation of an Automated Data Collection Method of Inflammatory Bowel Disease Medications in the National Veterans Affairs Healthcare System

1 Medical College of Wisconsin, Brookfield, Wisconsin, United States; 2 MCW, Milwaukee, Wisconsin, United States; 3 VA Medical Center, Milwaukee, Wisconsin, United States; 4 University of...

Julie Lorscheter ;

Paraj Patel ;

Colleen Veenendaal ;

Mary Whooley ;

Katherine Hoggatt ;

Salim Virani ;

Shirley Cohen-Mekelburg ;

Eman Mansoor ;

Jeffrey Whittle ;

Jason Hou ;

Raymond Cross , MD;

Saffia Bajwa ;

Preetika Sinh ;

Katherine Sherman ;

01/11/2024

P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study

BACKGROUND: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with on...

Stephen B. Hanauer , MD;

Michael Silver ;

Brian G. Feagan ;

Raymond Cross , MD;

David Hudesman , MD;

Douglas Wolf ;

Millie D. Long , MD, MPH;

Subrata Ghosh ;

AnnKatrin Petersen ;

Marc Pondel ;

12/15/2021

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator that selectively targets S1P 1 and S1P ...

Raymond Cross , MD;

Jonathan Calkwood ;

Ashwini Pai ;

Millie D. Long , MD, MPH;

Ayanbola Elegbe ;

James Sheffield ;

Douglas Wolf ;

Adil Javed ;

AnnKatrin Petersen ;

Marc Pondel ;

Lorna Charles ;

Harris A. Ahmad ;

12/15/2021

Podcast

IBD Drive Time: Importance of Diet in the Management of Crohn's Disease

05/25/2023

Raymond Cross , MD;

James D. Lewis ;

In the third episode of IBD Drive Time, host Raymond Cross, MD, discusses research into how diet can alleviate symptoms—or worsen disease—among patients with Crohn's disease with Dr James Lewis, who conducted the DINE-CD study.

In the third episode of IBD...

05/25/2023

Advances in Inflammatory Bowel Disease Network

Podcast

IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis

09/03/2024

Erin Forster , MD, MPH;

Millie D. Long , MD, MPH;

Raymond Cross , MD;

Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.

Dr Erin Forster of the Medical...

09/03/2024

Advances in Inflammatory Bowel Disease Network